MedTrace Logo

Misoprostol Dosing in BMI Greater Than 30

NCT05262738 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-07-03

Study results available
· View outcomes & findings →

Summary

The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.

Conditions

  • Pregnancy Related
  • Obesity
  • Labor Onset and Length Abnormalities

Interventions

DRUG

50 Micrograms Vaginal Misoprostol (Intervention)

Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.

DRUG

25 Micrograms Vaginal Misoprostol (Control)

Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.

Sponsors & Collaborators

  • University of Texas at Austin

    lead OTHER

Principal Investigators

  • Lorie Harper, MD, MSCI · Division Chief, Maternal-Fetal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-07-14
Completion
2023-07-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262738 on ClinicalTrials.gov